Mosepele Mosepele, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Botswana | 43 | 2024 | 1057 | 2.720 |
Why?
|
HIV Infections | 49 | 2024 | 17533 | 2.390 |
Why?
|
Meningitis, Cryptococcal | 9 | 2024 | 65 | 1.520 |
Why?
|
Albuminuria | 2 | 2024 | 660 | 0.860 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 281 | 0.640 |
Why?
|
Inflammasomes | 1 | 2024 | 543 | 0.640 |
Why?
|
Anti-HIV Agents | 11 | 2023 | 4559 | 0.620 |
Why?
|
Benzoxazines | 5 | 2019 | 320 | 0.590 |
Why?
|
Amphotericin B | 4 | 2022 | 140 | 0.550 |
Why?
|
Extracellular Matrix | 1 | 2024 | 1727 | 0.540 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2024 | 953 | 0.520 |
Why?
|
Cardiovascular Diseases | 5 | 2024 | 15652 | 0.470 |
Why?
|
Medication Adherence | 3 | 2023 | 2192 | 0.470 |
Why?
|
Caregivers | 2 | 2023 | 2307 | 0.450 |
Why?
|
HIV | 4 | 2023 | 1585 | 0.450 |
Why?
|
Cephalosporins | 3 | 2023 | 200 | 0.440 |
Why?
|
Hypertension | 2 | 2024 | 8626 | 0.440 |
Why?
|
Antifungal Agents | 5 | 2023 | 769 | 0.420 |
Why?
|
Developing Countries | 2 | 2022 | 2911 | 0.390 |
Why?
|
Bartonella Infections | 1 | 2011 | 21 | 0.390 |
Why?
|
Cell Adhesion Molecules | 1 | 2018 | 1612 | 0.380 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 2817 | 0.370 |
Why?
|
Cryptococcus neoformans | 2 | 2024 | 110 | 0.360 |
Why?
|
Carotid Artery Diseases | 1 | 2017 | 874 | 0.360 |
Why?
|
Viral Load | 6 | 2024 | 3386 | 0.350 |
Why?
|
Antigens, CD | 2 | 2018 | 4025 | 0.340 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1884 | 0.320 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2018 | 2203 | 0.320 |
Why?
|
Cross-Sectional Studies | 15 | 2024 | 26318 | 0.310 |
Why?
|
Flucytosine | 3 | 2023 | 31 | 0.290 |
Why?
|
Africa South of the Sahara | 6 | 2022 | 751 | 0.280 |
Why?
|
Fluconazole | 3 | 2023 | 154 | 0.270 |
Why?
|
Prevalence | 8 | 2024 | 15842 | 0.260 |
Why?
|
Anti-Retroviral Agents | 3 | 2021 | 1787 | 0.260 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4427 | 0.260 |
Why?
|
CD4 Lymphocyte Count | 5 | 2020 | 2587 | 0.250 |
Why?
|
Adult | 34 | 2024 | 223044 | 0.250 |
Why?
|
Hepatitis Delta Virus | 1 | 2024 | 24 | 0.240 |
Why?
|
Hepatitis D | 1 | 2024 | 23 | 0.230 |
Why?
|
Maternal Mortality | 2 | 2024 | 313 | 0.230 |
Why?
|
Pharmacology | 1 | 2004 | 97 | 0.230 |
Why?
|
Atherosclerosis | 2 | 2017 | 3424 | 0.230 |
Why?
|
Gammaproteobacteria | 1 | 2023 | 28 | 0.220 |
Why?
|
Wolves | 1 | 2023 | 10 | 0.210 |
Why?
|
Humans | 63 | 2024 | 765968 | 0.210 |
Why?
|
Cryptococcosis | 1 | 2024 | 99 | 0.210 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2024 | 198 | 0.210 |
Why?
|
Interleukin-18 | 1 | 2024 | 251 | 0.210 |
Why?
|
Male | 35 | 2024 | 363698 | 0.200 |
Why?
|
Dog Diseases | 1 | 2023 | 142 | 0.200 |
Why?
|
Pilot Projects | 7 | 2023 | 8733 | 0.200 |
Why?
|
Phylogeny | 3 | 2024 | 2832 | 0.190 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2024 | 2187 | 0.190 |
Why?
|
Proteinuria | 1 | 2024 | 607 | 0.190 |
Why?
|
Female | 38 | 2024 | 396112 | 0.190 |
Why?
|
Multicenter Studies as Topic | 2 | 2024 | 1731 | 0.190 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2022 | 664 | 0.180 |
Why?
|
Genotype | 6 | 2024 | 13024 | 0.180 |
Why?
|
Antiretroviral Therapy, Highly Active | 4 | 2020 | 1899 | 0.180 |
Why?
|
Problem-Based Learning | 1 | 2004 | 360 | 0.180 |
Why?
|
Middle Aged | 24 | 2024 | 223009 | 0.180 |
Why?
|
E-Selectin | 2 | 2023 | 576 | 0.170 |
Why?
|
Enterobacteriaceae Infections | 1 | 2022 | 189 | 0.170 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2023 | 694 | 0.170 |
Why?
|
Risk Factors | 9 | 2024 | 74840 | 0.160 |
Why?
|
Stillbirth | 4 | 2024 | 381 | 0.160 |
Why?
|
Self Efficacy | 1 | 2023 | 642 | 0.160 |
Why?
|
Pregnancy Outcome | 4 | 2024 | 2966 | 0.160 |
Why?
|
Health Occupations | 1 | 2020 | 226 | 0.160 |
Why?
|
Alkynes | 5 | 2019 | 326 | 0.160 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2019 | 618 | 0.160 |
Why?
|
HIV-1 | 4 | 2022 | 6944 | 0.150 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2023 | 1132 | 0.150 |
Why?
|
HIV Seropositivity | 2 | 2022 | 961 | 0.150 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2018 | 52 | 0.150 |
Why?
|
Quarantine | 1 | 2020 | 185 | 0.150 |
Why?
|
Cyclopropanes | 5 | 2019 | 437 | 0.150 |
Why?
|
Immune Evasion | 1 | 2022 | 377 | 0.150 |
Why?
|
Young Adult | 13 | 2024 | 59889 | 0.130 |
Why?
|
Research Personnel | 1 | 2021 | 590 | 0.130 |
Why?
|
Tuberculosis | 2 | 2023 | 2012 | 0.130 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2018 | 295 | 0.120 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2018 | 423 | 0.120 |
Why?
|
Education, Medical, Undergraduate | 1 | 2004 | 1085 | 0.120 |
Why?
|
Quinolines | 1 | 2020 | 769 | 0.120 |
Why?
|
Antihypertensive Agents | 1 | 2024 | 2033 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1159 | 0.120 |
Why?
|
Case-Control Studies | 5 | 2018 | 22223 | 0.110 |
Why?
|
Drug Costs | 2 | 2019 | 1193 | 0.110 |
Why?
|
Monobactams | 2 | 2023 | 16 | 0.110 |
Why?
|
Motivation | 1 | 2023 | 2018 | 0.110 |
Why?
|
Sexual Partners | 1 | 2018 | 804 | 0.110 |
Why?
|
Premature Birth | 2 | 2022 | 1829 | 0.110 |
Why?
|
Personal Satisfaction | 1 | 2017 | 641 | 0.110 |
Why?
|
Comorbidity | 4 | 2021 | 10563 | 0.100 |
Why?
|
Plaque, Atherosclerotic | 1 | 2024 | 1529 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 2007 | 0.100 |
Why?
|
Bartonella quintana | 1 | 2011 | 3 | 0.100 |
Why?
|
Trench Fever | 1 | 2011 | 2 | 0.100 |
Why?
|
Self Report | 1 | 2024 | 3770 | 0.100 |
Why?
|
Malawi | 2 | 2024 | 315 | 0.100 |
Why?
|
Bartonella | 1 | 2011 | 11 | 0.100 |
Why?
|
Bartonella henselae | 1 | 2011 | 15 | 0.100 |
Why?
|
American Heart Association | 1 | 2017 | 1047 | 0.100 |
Why?
|
Cat-Scratch Disease | 1 | 2011 | 23 | 0.100 |
Why?
|
Patients | 1 | 2018 | 910 | 0.090 |
Why?
|
Attitude to Health | 1 | 2020 | 2020 | 0.090 |
Why?
|
Program Development | 1 | 2017 | 1295 | 0.090 |
Why?
|
Social Support | 1 | 2021 | 2192 | 0.090 |
Why?
|
Glomerular Filtration Rate | 1 | 2020 | 2233 | 0.090 |
Why?
|
Curriculum | 2 | 2020 | 3782 | 0.090 |
Why?
|
Central Nervous System | 1 | 2018 | 1341 | 0.090 |
Why?
|
Emergency Medical Services | 1 | 2022 | 1938 | 0.090 |
Why?
|
Treatment Outcome | 7 | 2024 | 65188 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2021 | 5302 | 0.090 |
Why?
|
Drug Resistance, Microbial | 2 | 2023 | 833 | 0.080 |
Why?
|
Heart Diseases | 1 | 2022 | 2821 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2018 | 2589 | 0.080 |
Why?
|
Pregnancy Complications | 1 | 2022 | 2975 | 0.080 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 2008 | 110 | 0.070 |
Why?
|
Interleukin-6 | 1 | 2018 | 3222 | 0.070 |
Why?
|
Mental Disorders | 2 | 2022 | 6853 | 0.070 |
Why?
|
Blood Pressure | 1 | 2023 | 8532 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2022 | 4850 | 0.070 |
Why?
|
Cost-Benefit Analysis | 4 | 2022 | 5526 | 0.070 |
Why?
|
Monocytes | 1 | 2017 | 2595 | 0.070 |
Why?
|
Primary Health Care | 1 | 2024 | 4736 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7478 | 0.070 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 246 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10383 | 0.070 |
Why?
|
South Africa | 2 | 2023 | 1867 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2023 | 6309 | 0.070 |
Why?
|
Electronic Health Records | 1 | 2024 | 4873 | 0.070 |
Why?
|
Cognition Disorders | 2 | 2011 | 3967 | 0.070 |
Why?
|
Health Expenditures | 1 | 2019 | 2387 | 0.070 |
Why?
|
Immunocompromised Host | 1 | 2011 | 866 | 0.060 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2310 | 0.060 |
Why?
|
Social Stigma | 2 | 2023 | 788 | 0.060 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2136 | 0.060 |
Why?
|
Outpatients | 2 | 2024 | 1595 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8041 | 0.060 |
Why?
|
Communicable Disease Control | 2 | 2022 | 856 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5446 | 0.060 |
Why?
|
RNA, Ribosomal, 28S | 1 | 2024 | 9 | 0.060 |
Why?
|
Agar | 1 | 2023 | 51 | 0.060 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4040 | 0.050 |
Why?
|
Vitamin D Deficiency | 1 | 2012 | 1348 | 0.050 |
Why?
|
Chronic Disease | 1 | 2018 | 9347 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2024 | 11499 | 0.050 |
Why?
|
Hydrolases | 1 | 2023 | 146 | 0.050 |
Why?
|
Mutation | 2 | 2024 | 30198 | 0.050 |
Why?
|
Hospital Mortality | 1 | 2016 | 5343 | 0.050 |
Why?
|
Time Factors | 3 | 2018 | 40065 | 0.050 |
Why?
|
Clinical Competence | 1 | 2017 | 4863 | 0.050 |
Why?
|
Adolescent | 4 | 2023 | 88835 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 16047 | 0.050 |
Why?
|
Depression | 2 | 2012 | 8237 | 0.050 |
Why?
|
Carbapenems | 1 | 2022 | 125 | 0.050 |
Why?
|
Hepatitis B virus | 1 | 2024 | 530 | 0.040 |
Why?
|
Pregnancy | 4 | 2024 | 30260 | 0.040 |
Why?
|
Australia | 1 | 2004 | 1258 | 0.040 |
Why?
|
Treatment Failure | 2 | 2017 | 2652 | 0.040 |
Why?
|
Statistical Distributions | 1 | 2020 | 60 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5508 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9747 | 0.040 |
Why?
|
Placebos | 1 | 2024 | 1659 | 0.040 |
Why?
|
Hospitals | 2 | 2023 | 3888 | 0.040 |
Why?
|
Standard of Care | 1 | 2023 | 567 | 0.040 |
Why?
|
Universities | 1 | 2004 | 998 | 0.040 |
Why?
|
Hepatitis B | 1 | 2024 | 707 | 0.040 |
Why?
|
Vitamin D | 1 | 2012 | 3272 | 0.040 |
Why?
|
Personnel Loyalty | 1 | 2017 | 11 | 0.040 |
Why?
|
Dogs | 1 | 2023 | 3822 | 0.040 |
Why?
|
Authorship | 1 | 2021 | 288 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2020 | 469 | 0.040 |
Why?
|
Prospective Studies | 5 | 2023 | 54802 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2022 | 866 | 0.040 |
Why?
|
Aged | 4 | 2024 | 171117 | 0.040 |
Why?
|
Internship and Residency | 1 | 2017 | 5946 | 0.040 |
Why?
|
Faculty | 1 | 2020 | 384 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14751 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 2022 | 1525 | 0.030 |
Why?
|
Chest Pain | 1 | 2024 | 1100 | 0.030 |
Why?
|
Teaching | 1 | 2004 | 1169 | 0.030 |
Why?
|
Health Personnel | 2 | 2020 | 3390 | 0.030 |
Why?
|
Alleles | 2 | 2018 | 6897 | 0.030 |
Why?
|
Hospitalization | 1 | 2016 | 10808 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2023 | 21056 | 0.030 |
Why?
|
Oxazines | 1 | 2018 | 358 | 0.030 |
Why?
|
Poverty | 2 | 2022 | 2714 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2011 | 10429 | 0.030 |
Why?
|
Cohort Studies | 4 | 2020 | 41649 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2024 | 1342 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 24282 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2121 | 0.030 |
Why?
|
Focus Groups | 1 | 2021 | 1459 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2020 | 999 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2024 | 6069 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5370 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 878 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 4015 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2024 | 2193 | 0.030 |
Why?
|
Placenta | 1 | 2023 | 1728 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2024 | 26346 | 0.030 |
Why?
|
Pyridones | 1 | 2018 | 816 | 0.030 |
Why?
|
Bacteria | 1 | 2024 | 2209 | 0.030 |
Why?
|
Qualitative Research | 1 | 2023 | 3139 | 0.020 |
Why?
|
Life Style | 1 | 2024 | 3926 | 0.020 |
Why?
|
Heart Failure | 1 | 2016 | 11840 | 0.020 |
Why?
|
Activities of Daily Living | 2 | 2012 | 2415 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2010 | 0.020 |
Why?
|
Models, Molecular | 1 | 2022 | 5379 | 0.020 |
Why?
|
Infant | 2 | 2024 | 36386 | 0.020 |
Why?
|
Escherichia coli | 1 | 2023 | 4214 | 0.020 |
Why?
|
Schools, Medical | 1 | 2017 | 876 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2012 | 6014 | 0.020 |
Why?
|
Inpatients | 1 | 2022 | 2564 | 0.020 |
Why?
|
Age Factors | 2 | 2019 | 18380 | 0.020 |
Why?
|
Counseling | 1 | 2018 | 1551 | 0.020 |
Why?
|
Cardiovascular Agents | 1 | 2016 | 851 | 0.020 |
Why?
|
AIDS Dementia Complex | 1 | 2010 | 154 | 0.020 |
Why?
|
Program Evaluation | 1 | 2017 | 2499 | 0.020 |
Why?
|
RNA, Viral | 1 | 2017 | 2864 | 0.020 |
Why?
|
United States | 1 | 2017 | 72903 | 0.020 |
Why?
|
Behavior | 1 | 2011 | 535 | 0.020 |
Why?
|
Piperazines | 1 | 2018 | 2549 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2016 | 1736 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2011 | 7123 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10729 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 2011 | 770 | 0.020 |
Why?
|
Health Behavior | 1 | 2018 | 2650 | 0.020 |
Why?
|
Odds Ratio | 1 | 2018 | 9649 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7232 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9591 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10070 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12056 | 0.010 |
Why?
|
Child | 2 | 2023 | 80564 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39193 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2016 | 5125 | 0.010 |
Why?
|
Urban Population | 1 | 2012 | 2040 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8703 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2016 | 3928 | 0.010 |
Why?
|
Logistic Models | 1 | 2018 | 13266 | 0.010 |
Why?
|
Cognition | 2 | 2011 | 7049 | 0.010 |
Why?
|
Length of Stay | 1 | 2016 | 6485 | 0.010 |
Why?
|
Sex Factors | 1 | 2016 | 10603 | 0.010 |
Why?
|
Haplotypes | 1 | 2008 | 2728 | 0.010 |
Why?
|
Suicide | 1 | 2012 | 1604 | 0.010 |
Why?
|
Memory | 1 | 2010 | 2190 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2012 | 7838 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2022 | 59489 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21480 | 0.010 |
Why?
|
Animals | 1 | 2023 | 168764 | 0.010 |
Why?
|